Hareesh Jayakumar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hareesh Jayakumar has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Amalendu P. Ranjan
Department of Microbiology, Immunology and Genetics, University of North Texas Health Science Center, Fort Worth, TX 76107, USA
1 shared publication - Bruce A. Bunnell
Department of Microbiology, Immunology and Genetics, University of North Texas Health Science Center, Fort Worth, TX 76107, USA
1 shared publication - Ezek Mathew
Department of Microbiology and Immunology, The University of North Texas Health Science Center, 3500 Camp Bowie Blvd, Fort Worth, TX 76107, USA
1 shared publication - Luis M. Colon-Perez
Department of Pharmacology & Neuroscience, University of North Texas Health Science Center, Fort Worth, TX
1 shared publication - Luke C. Cooksey
Department of Microbiology, Immunology and Genetics, University of North Texas Health, Fort Worth, TX 76107, USA
1 shared publication - Mariana Moguel Mendez
Burnette School of Medicine, Texas Christian University, Fort Worth, TX 76109, USA
1 shared publication
Latest Publications
- Open Access
- 30 April 2026
- Published by MDPI AG in Brain Sciences
- Vol. 16 (5) , 487
Evolving Landscape of Glioblastoma Research: Integrating Therapeutic Advances and Diagnostic Frontiers
Glioblastoma (GB) remains the most aggressive primary brain malignancy, with the Stupp regimen persisting as the standard of care for nearly two decades despite poor survival outcomes. This review was synthesized by extensively reviewing and analyzing the literature from PubMed, Scopus, and Web of Science to evaluate the emerging promising therapeutic and diagnostic strategies for combating GB. Results indicate significant progress in molecularly targeted therapies, biomimetic nanocarriers, and advanced radiotherapy. While immunotherapeutic approaches, such as checkpoint inhibitors and vaccines, show variable clinical success, the integration of bioinformatics and machine learning has significantly enhanced treatment response prediction. Furthermore, advances in radiomics and molecular imaging have improved the differentiation between true tumor progression and pseudoprogression, potentially reducing invasive diagnostic requirements. Additionally, other emerging and investigational adjuvant therapeutic approaches have shown promise. We conclude that, while multimodal strategies integrating molecular and computational approaches offer a path toward personalized GB management, significant barriers—namely tumor heterogeneity and the blood–brain barrier—persist. Future research must prioritize precision-based combinatorial models to successfully translate these preclinical advancements into improved clinical outcomes for patients.
- 30 April 2026
- Published by MDPI AG in Brain Sciences
- Vol. 16 (5) , 487
Open AccessEvolving Landscape of Glioblastoma Research: Integrating Therapeutic Advances and Diagnostic Frontiers
Glioblastoma (GB) remains the most aggressive primary brain malignancy, with the Stupp regimen persisting as the standard of care for nearly two decades despite poor survival outcomes. This review was synthesized by extensively reviewing and analyzing the literature from PubMed, Scopus, and Web of Science to evaluate the emerging promising therapeutic and diagnostic strategies for combating GB. Results indicate significant progress in molecularly targeted therapies, biomimetic nanocarriers, and advanced radiotherapy. While immunotherapeutic approaches, such as checkpoint inhibitors and vaccines, show variable clinical success, the integration of bioinformatics and machine learning has significantly enhanced treatment response prediction. Furthermore, advances in radiomics and molecular imaging have improved the differentiation between true tumor progression and pseudoprogression, potentially reducing invasive diagnostic requirements. Additionally, other emerging and investigational adjuvant therapeutic approaches have shown promise. We conclude that, while multimodal strategies integrating molecular and computational approaches offer a path toward personalized GB management, significant barriers—namely tumor heterogeneity and the blood–brain barrier—persist. Future research must prioritize precision-based combinatorial models to successfully translate these preclinical advancements into improved clinical outcomes for patients.